Clinical Recommendations for the Use of Donepezil 23 mg in Moderate-to-Severe Alzheimer's Disease in the Asia-Pacific Region
© 2016 The Author(s) Published by S. Karger AG, Basel. Background: The 'Asia-Pacific Expert Panel (APEX) for donepezil 23 mg' met in November 2015 to review evidence for the recently approved high dose of donepezil and to provide recommendations to help physicians in Asia make informed cli...
Saved in:
Main Authors: | , , , , , , , , , , , , , |
---|---|
Other Authors: | |
Format: | Review |
Published: |
2018
|
Subjects: | |
Online Access: | https://repository.li.mahidol.ac.th/handle/123456789/41174 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Mahidol University |
id |
th-mahidol.41174 |
---|---|
record_format |
dspace |
spelling |
th-mahidol.411742019-03-14T15:02:06Z Clinical Recommendations for the Use of Donepezil 23 mg in Moderate-to-Severe Alzheimer's Disease in the Asia-Pacific Region Marwan Sabbagh Seolheui Han Sangyun Kim Hae Ri Na Jae Hong Lee Nagaendran Kandiah Kammant Phanthumchinda Chuthamanee Suthisisang Vorapun Senanarong Ming Chyi Pai Diatri Narilastri Ajit M. Sowani Encarnita Ampil Amitabh Dash Barrow Neurological Institute Konkuk University Seoul National University Bundang Hospital Seoul National University College of Medicine Bobath Memorial Hospital University of Ulsan, College of Medicine Duke-NUS Medical School Singapore Chulalongkorn University Mahidol University National Cheng Kung University University of Indonesia, RSUPN Dr. Cipto Mangunkusumo SAL Hospital and Medical Institute University of Santo Tomas Hospital Eisai Pharmaceuticals India Pvt. Ltd. Medicine © 2016 The Author(s) Published by S. Karger AG, Basel. Background: The 'Asia-Pacific Expert Panel (APEX) for donepezil 23 mg' met in November 2015 to review evidence for the recently approved high dose of donepezil and to provide recommendations to help physicians in Asia make informed clinical decisions about using donepezil 23 mg in patients with moderate-to-severe Alzheimer's disease (AD). Summary: In a global phase III study (study 326) in patients with moderate-to-severe AD, donepezil 23 mg/day demonstrated significantly greater cognitive benefits versus donepezil 10 mg/day, with a between-treatment difference in mean change in the Severe Impairment Battery score of 2.2 points (p < 0.001) in the overall population and 3.1 points (p < 0.001) in patients with advanced AD. A subanalysis of study 326 demonstrated that the benefits and risks associated with donepezil 23 mg/day versus donepezil 10 mg/day in Asian patients with moderate-to-severe AD were comparable to those in the global study population. Key Message: Donepezil 23 mg is a valuable treatment for patients with AD, particularly those with advanced disease. The APEX emphasized the importance of patient selection (AD severity, tolerability of lower doses of donepezil, and absence of contraindications), a stepwise titration strategy for dose escalation, and appropriate monitoring and counseling of patients and caregivers in the management of patients with AD. 2018-12-11T03:25:44Z 2019-03-14T08:02:06Z 2018-12-11T03:25:44Z 2019-03-14T08:02:06Z 2016-09-09 Review Dementia and Geriatric Cognitive Disorders Extra. Vol.6, No.3 (2016), 382-395 10.1159/000448214 16645464 2-s2.0-84988350405 https://repository.li.mahidol.ac.th/handle/123456789/41174 Mahidol University SCOPUS https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84988350405&origin=inward |
institution |
Mahidol University |
building |
Mahidol University Library |
continent |
Asia |
country |
Thailand Thailand |
content_provider |
Mahidol University Library |
collection |
Mahidol University Institutional Repository |
topic |
Medicine |
spellingShingle |
Medicine Marwan Sabbagh Seolheui Han Sangyun Kim Hae Ri Na Jae Hong Lee Nagaendran Kandiah Kammant Phanthumchinda Chuthamanee Suthisisang Vorapun Senanarong Ming Chyi Pai Diatri Narilastri Ajit M. Sowani Encarnita Ampil Amitabh Dash Clinical Recommendations for the Use of Donepezil 23 mg in Moderate-to-Severe Alzheimer's Disease in the Asia-Pacific Region |
description |
© 2016 The Author(s) Published by S. Karger AG, Basel. Background: The 'Asia-Pacific Expert Panel (APEX) for donepezil 23 mg' met in November 2015 to review evidence for the recently approved high dose of donepezil and to provide recommendations to help physicians in Asia make informed clinical decisions about using donepezil 23 mg in patients with moderate-to-severe Alzheimer's disease (AD). Summary: In a global phase III study (study 326) in patients with moderate-to-severe AD, donepezil 23 mg/day demonstrated significantly greater cognitive benefits versus donepezil 10 mg/day, with a between-treatment difference in mean change in the Severe Impairment Battery score of 2.2 points (p < 0.001) in the overall population and 3.1 points (p < 0.001) in patients with advanced AD. A subanalysis of study 326 demonstrated that the benefits and risks associated with donepezil 23 mg/day versus donepezil 10 mg/day in Asian patients with moderate-to-severe AD were comparable to those in the global study population. Key Message: Donepezil 23 mg is a valuable treatment for patients with AD, particularly those with advanced disease. The APEX emphasized the importance of patient selection (AD severity, tolerability of lower doses of donepezil, and absence of contraindications), a stepwise titration strategy for dose escalation, and appropriate monitoring and counseling of patients and caregivers in the management of patients with AD. |
author2 |
Barrow Neurological Institute |
author_facet |
Barrow Neurological Institute Marwan Sabbagh Seolheui Han Sangyun Kim Hae Ri Na Jae Hong Lee Nagaendran Kandiah Kammant Phanthumchinda Chuthamanee Suthisisang Vorapun Senanarong Ming Chyi Pai Diatri Narilastri Ajit M. Sowani Encarnita Ampil Amitabh Dash |
format |
Review |
author |
Marwan Sabbagh Seolheui Han Sangyun Kim Hae Ri Na Jae Hong Lee Nagaendran Kandiah Kammant Phanthumchinda Chuthamanee Suthisisang Vorapun Senanarong Ming Chyi Pai Diatri Narilastri Ajit M. Sowani Encarnita Ampil Amitabh Dash |
author_sort |
Marwan Sabbagh |
title |
Clinical Recommendations for the Use of Donepezil 23 mg in Moderate-to-Severe Alzheimer's Disease in the Asia-Pacific Region |
title_short |
Clinical Recommendations for the Use of Donepezil 23 mg in Moderate-to-Severe Alzheimer's Disease in the Asia-Pacific Region |
title_full |
Clinical Recommendations for the Use of Donepezil 23 mg in Moderate-to-Severe Alzheimer's Disease in the Asia-Pacific Region |
title_fullStr |
Clinical Recommendations for the Use of Donepezil 23 mg in Moderate-to-Severe Alzheimer's Disease in the Asia-Pacific Region |
title_full_unstemmed |
Clinical Recommendations for the Use of Donepezil 23 mg in Moderate-to-Severe Alzheimer's Disease in the Asia-Pacific Region |
title_sort |
clinical recommendations for the use of donepezil 23 mg in moderate-to-severe alzheimer's disease in the asia-pacific region |
publishDate |
2018 |
url |
https://repository.li.mahidol.ac.th/handle/123456789/41174 |
_version_ |
1763488791515889664 |